🔓 Unlock the full profile of Raja Srinivas (Asimov), including verified contact details, financial insights, and professional associations.

See Raja Srinivas Full Profile

Below are the ✅ Verified Contact Details to help you connect directly:

Email: raj*****@asi******.com

Mobile: 65036*****

Estimated Net Worth 💰 : ₹0 – ₹500+ Cr (approx. $0 – $60M)

Key Insights You Should Know About This Individual

  • Raja Srinivas is the founder of Asimov, a company established in 2017, located in Cambridge, Massachusetts, focusing on innovative solutions in biotechnology.
  • Asimov aims to leverage technology to enhance research and development processes, particularly in the field of synthetic biology.
  • Prior to founding Asimov, Raja served as a co-founder and advisor at Novopyxis, contributing to advancements in biotechnological applications from 2013 to 2017.
  • Raja completed a PhD research program at the Massachusetts Institute of Technology (MIT) from 2011 to 2016, honing expertise in biotechnology and its applications.
  • Raja's academic journey includes serving as an undergraduate research assistant at The Johns Hopkins University between 2008 and 2011, contributing to critical research projects.
  • During the time at The Johns Hopkins University, Raja also held the position of Design Team Leader, showcasing leadership capabilities and project management skills.
  • Raja was an undergraduate research fellow at the National Cancer Institute (NCI) in 2009, gaining valuable research experience in a prestigious institute.
  • A research assistant role at the University at Buffalo (UB) from 2005 to 2007 further solidified Raja's foundation in research methodologies and biological sciences.
  • Raja has been active in expanding Asimov's presence and impact in the biotechnology sector, as indicated by the company's efforts in technological integration and innovation.
  • Asimov has seen fluctuations in organizational growth, with a noted decline in headcount over recent periods, reflecting the challenges faced in the rapidly evolving biotechnology landscape.